Universal Beteiligungs und Servicegesellschaft mbH Has $4 Million Stake in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Universal Beteiligungs reduced its stake in Supernus by 26.8% in Q4, selling 29,390 shares and now holding 80,446 shares worth about $3.998 million (≈0.14% of the company).
• Insider selling has been significant: insiders sold 120,881 shares (~$6.14M) over the past three months, including VP Padmanabh Bhatt's 50,000‑share sale for $2.514M, leaving insiders with 8.8% ownership.
• Supernus stock opened at $48.55 with a $2.8B market cap and a negative PE (-71.4); analysts' consensus is a "Hold" with a $62.17 target (4 Buy, 2 Hold, 1 Sell).

Universal Beteiligungs und Servicegesellschaft mbH lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 26.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 80,446 shares of the specialty pharmaceutical company's stock after selling 29,390 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.14% of Supernus Pharmaceuticals worth $3,998,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Jefferies Financial Group Inc. raised its position in shares of Supernus Pharmaceuticals by 62.0% during the third quarter. Jefferies Financial Group Inc. now owns 86,179 shares of the specialty pharmaceutical company's stock valued at $4,118,000 after buying an additional 32,979 shares during the last quarter. Ruffer LLP acquired a new position in shares of Supernus Pharmaceuticals during the third quarter valued at about $2,647,000. Tudor Investment Corp ET AL acquired a new position in shares of Supernus Pharmaceuticals during the third quarter valued at about $1,434,000. Phocas Financial Corp. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $4,042,000. Finally, Teacher Retirement System of Texas raised its position in shares of Supernus Pharmaceuticals by 648.9% during the third quarter. Teacher Retirement System of Texas now owns 112,638 shares of the specialty pharmaceutical company's stock valued at $5,383,000 after buying an additional 97,597 shares during the last quarter.

Supernus Pharmaceuticals Stock Down 0.3%

NASDAQ:SUPN opened at $48.55 on Thursday. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $59.68. The firm has a market capitalization of $2.80 billion, a PE ratio of -71.40, a price-to-earnings-growth ratio of 1.56 and a beta of 0.73. The firm has a 50-day moving average price of $51.21 and a 200 day moving average price of $49.90.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SUPN shares. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Sunday, March 8th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Monday. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $62.17.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 50,000 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $50.28, for a total transaction of $2,514,000.00. Following the sale, the vice president directly owned 17,044 shares of the company's stock, valued at approximately $856,972.32. This represents a 74.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bethany Sensenig sold 4,475 shares of the company's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $51.01, for a total transaction of $228,269.75. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 120,881 shares of company stock valued at $6,139,356. Corporate insiders own 8.80% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.